How Ozempic Can Help Reshape Your Food Habits
People who start on a GLP-1 tend to describe the same thing, and it rarely sounds like a diet. They say the constant background chatter about food — what's in the fridge, what's for later, whether there's something in the drawer — simply goes quiet. That experience has a name now, and it has a biological explanation. It also has nine years of clinical evidence behind it, including two of the largest outcome trials ever run in this field.
What Ozempic is, and what it's licensed to do
Ozempic is Novo Nordisk's brand name for semaglutide, a once-weekly injection first approved by the FDA in December 2017. It is a GLP-1 receptor agonist — a modified, longer-lasting version of a hormone your gut already produces after every meal.
Nine years on, it carries the widest set of approved indications of any medicine in its class:
- Blood sugar control in adults with type 2 diabetes, alongside diet and exercise
- Reducing major cardiovascular events — cardiovascular death, heart attack and stroke — in adults with type 2 diabetes and established heart disease
- Protecting kidney function in adults with type 2 diabetes and chronic kidney disease, added in January 2025, reducing the risk of kidney disease worsening, kidney failure and cardiovascular death
That third approval made Ozempic the first and only GLP-1 receptor agonist licensed for kidney outcomes. It is worth pausing on what that represents: a drug that started as a glucose-lowering agent has accumulated evidence that it protects the two organ systems diabetes most reliably damages.
Food noise, and why willpower was never the problem
For decades, the standard explanation for why diets fail was character. Not enough discipline, not enough consistency, not enough want-it-badly-enough. Anyone who has actually tried knows that explanation never quite fitted the experience.
The biology tells a different story. Appetite is not a decision — it is a signalling system, and in many people that system runs loud.
GLP-1 receptors sit in the hypothalamus and the brainstem, the regions that govern hunger and fullness. When semaglutide activates them, the brain receives a stronger and earlier version of the signal it normally gets only after a substantial meal. The effect builds gradually over the first few weeks as those circuits recalibrate.
What makes this different from appetite suppressants of the past is where it happens. This is subcortical signalling — beneath conscious control, in the same way you cannot decide to stop feeling cold. People consistently describe it not as resisting food successfully, but as the urge simply not arriving. Hunger becomes absence rather than a battle.
There is a second layer. GLP-1 signalling also dampens dopamine responses in the brain's reward circuitry, which is why the shift is not only in how much people want to eat but in what they want. Relative preference for fatty, energy-dense food drops. Brain imaging studies show reduced activation in food-reward regions alongside strengthened satiety networks.
This is the mechanistic reason GLP-1 medicines succeeded where willpower-based approaches did not. They do not ask you to fight the signal harder. They turn the signal down.
The three other things it does
Appetite is the part people feel. Three further mechanisms run alongside it.
Glucose-dependent insulin release. Semaglutide prompts the pancreas to release insulin — but only when blood sugar is elevated. When glucose is normal, the signal quiets. This is the structural reason GLP-1 medicines, used on their own, rarely cause hypoglycaemia, unlike insulin or sulfonylureas, which push insulin out regardless.
Glucagon suppression. Glucagon instructs the liver to release stored glucose. Semaglutide suppresses it during high blood sugar while leaving the protective glucagon response intact when blood sugar drops — a genuinely elegant piece of physiology.
Delayed gastric emptying. Food leaves the stomach more slowly, which flattens the post-meal glucose spike and extends fullness well past the meal itself.
What nine years of trials found
Semaglutide has one of the deepest evidence files in modern medicine. Three programmes matter most.
SUSTAIN — the glycaemic foundation
The SUSTAIN programme evaluated semaglutide in over 8,000 people with type 2 diabetes, across the full spectrum of disease. It delivered superior and sustained blood sugar control and weight loss against every comparator it was tested against.
SUSTAIN-6 then examined cardiovascular outcomes in 3,297 people at high cardiovascular risk over 104 weeks. Semaglutide significantly reduced the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke, with a hazard ratio of 0.74.
SELECT — the trial that reframed obesity treatment
SELECT is the one cardiologists talk about. It enrolled 17,604 adults across 41 countries — aged 45 and over, BMI of 27 or higher, with established cardiovascular disease but no diabetes — and followed them for roughly 40 months.
Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20%. All three components of the endpoint contributed. Participants lost an average of 9.4% of body weight.
Why this mattered so much: treating high cholesterol and high blood pressure to prevent heart attacks was long-established practice, but there had never been evidence that treating obesity itself improved cardiovascular outcomes. SELECT supplied it. And a subsequent analysis found the cardiovascular benefit was not fully explained by the weight loss — meaning the drug appears to be doing protective work through additional pathways.
FLOW — the kidney trial
FLOW tested once-weekly semaglutide against placebo in adults with type 2 diabetes and chronic kidney disease. It produced a 24% relative risk reduction in the composite of kidney disease progression, kidney failure and cardiovascular death — a 4.9% absolute risk reduction at three years. This is the trial behind the 2025 kidney approval.
| Trial | Population | Headline result |
|---|---|---|
| SUSTAIN 1–7 | 8,000+ adults with type 2 diabetes | Superior blood sugar control and weight loss vs all comparators |
| SUSTAIN-6 | 3,297 at high cardiovascular risk | Significant reduction in cardiovascular events (HR 0.74) |
| SELECT | 17,604 with obesity + heart disease, no diabetes | 20% fewer major cardiovascular events; 9.4% weight loss |
| FLOW | Type 2 diabetes with chronic kidney disease | 24% reduction in kidney disease progression and CV death |
The headline evidence
- 17,604 people, 41 countries in the SELECT cardiovascular trial
- 20% reduction in major adverse cardiovascular events
- 24% reduction in kidney disease progression in FLOW
- 4 years of sustained weight loss in the longest follow-up
- Fewer serious adverse events on semaglutide than on placebo in SELECT
Does the weight loss hold? The four-year answer
The most common worry about GLP-1 medicines is that the effect fades — that the body adapts, the drug stops working, and the weight returns while you are still taking it.
SELECT is the best available answer, because it followed participants for four years rather than the usual one or two.
Weight loss continued for roughly 65 weeks and then held steady through 208 weeks. At the four-year mark, the semaglutide group showed a mean 10.2% weight reduction against 1.5% for placebo, with waist circumference down 7.7 cm versus 1.3 cm. Meaningful weight loss occurred across both sexes, every body size, every race and every region studied.
The plateau is not the drug failing. It is the body arriving at a new equilibrium and staying there — which is precisely what you want from a maintenance therapy.
One finding from that same analysis deserves more attention than it gets. Rates of serious adverse events were lower in the semaglutide group than the placebo group, in every BMI category. For a drug this widely discussed, that is a reassuring result and one that rarely makes it into the coverage.
Who this isn't for
Semaglutide carries a boxed warning for thyroid C-cell tumours. The context matters: this comes from rodent studies, where semaglutide produced these tumours at clinically relevant exposures. Whether the finding translates to humans remains undetermined, and no confirmed human cases have been attributed to the drug across its clinical trial programme. The warning drives a specific and narrow exclusion rather than a general caution.
Ozempic is not used by anyone with a personal or family history of medullary thyroid carcinoma, anyone with Multiple Endocrine Neoplasia syndrome type 2, or anyone with a known serious hypersensitivity to semaglutide.
Ordinary thyroid conditions do not appear on that list. Hashimoto's, Graves' disease, hypothyroidism on levothyroxine, benign nodules and thyroid surgery for non-medullary reasons all sit well outside the contraindication.
A few situations warrant a conversation before starting rather than a hard stop: a history of pancreatitis, existing diabetic retinopathy (SUSTAIN-6 recorded a signal of retinopathy progression in the semaglutide arm), gallbladder disease, and any regimen that already includes insulin or a sulfonylurea — the last because hypoglycaemia risk rises meaningfully in combination, and those doses usually need adjusting.
Ozempic, Wegovy, Rybelsus: one molecule, three products
All three contain semaglutide. The differences are dose, format and licensed indication.
| Ozempic | Wegovy | Rybelsus | |
|---|---|---|---|
| Format | Weekly injection | Weekly injection | Daily tablet |
| Doses | 0.5, 1, 2 mg | Up to 2.4 mg | Oral |
| Primary licence | Type 2 diabetes | Weight management | Type 2 diabetes |
| Also licensed for | Cardiovascular and kidney outcomes | Cardiovascular risk reduction; adolescents from 12 | — |
Because Ozempic's doses run lower than Wegovy's, its reported side effect rates are correspondingly lower — the same molecule behaves differently at different exposures. It is the same reason weight loss figures differ between the two.
Semaglutide as a research compound
Alongside its life as a prescription medicine, semaglutide is one of the most actively studied molecules in metabolic research. Laboratories worldwide are investigating GLP-1 signalling in areas well beyond glucose and appetite — reward circuitry, inflammation, kidney physiology, neuroprotection. The mechanistic findings described earlier in this article came from exactly that kind of work.
Research-grade material serves that laboratory context, and the standard that matters most in it is verification. Peptide identity and purity are not visible to the eye, which is why independent third-party analysis is the baseline for credible research supply rather than an optional extra.
Everything in our catalogue is supplied with third-party testing, and the results are published openly in our COA database — including semaglutide, tirzepatide and the triple agonist retatrutide. Compounds in this class are also cold-chain sensitive, so handling and storage conditions matter as much as the certificate does.
Explore the metabolic research category
Research-grade GLP-1 and incretin compounds, every batch third-party tested with results published openly, shipped under controlled cold-chain conditions.
View metabolic peptidesFrequently asked questions
What is "food noise"?
It's the term people use for the persistent background preoccupation with food — planning it, anticipating it, resisting it. GLP-1 receptors in the hypothalamus and brainstem regulate that signalling, and semaglutide amplifies satiety signals while dampening food-reward responses. Most people describe the hunger not as easier to resist but as simply absent.
Does the weight loss last, or does the drug stop working?
In SELECT, the longest follow-up available, weight loss continued for around 65 weeks and then held steady through 208 weeks — four years. At that point the semaglutide group showed a mean 10.2% reduction versus 1.5% for placebo. The plateau reflects a new equilibrium rather than the drug losing effect.
How long do the side effects last?
Digestive symptoms peak in the first two to four weeks and after each dose increase, then fade. Pooled SUSTAIN data found the median nausea episode lasted roughly 8 to 14 days. Between 3.1% and 6.8% of trial participants stopped because of them. Following the titration schedule rather than compressing it makes a substantial difference.
Does Ozempic cause low blood sugar?
Rarely on its own, because its insulin effect is glucose-dependent — the signal amplifies when blood sugar is high and quiets when it isn't. The protective glucagon response during low blood sugar also stays intact. Risk rises when combined with insulin or a sulfonylurea, which is why those doses are usually adjusted.
What's the difference between Ozempic and Wegovy?
Same molecule, different doses and licences. Ozempic runs at 0.5–2 mg and is licensed for type 2 diabetes plus cardiovascular and kidney outcomes. Wegovy goes to 2.4 mg and holds the weight-management licence along with cardiovascular risk reduction. Lower doses mean Ozempic's side effect rates run lower too.
Is Ozempic safe long term?
It has one of the longest and largest safety records in the class — approved since 2017, with SELECT following more than 17,000 people for around four years. In that trial, rates of serious adverse events were lower on semaglutide than on placebo across every BMI category. It carries a boxed warning for thyroid C-cell tumours based on rodent data, with human relevance undetermined and no confirmed human cases attributed in trials.
The bottom line
Ozempic started as a blood sugar medicine and turned into something considerably more interesting. Nine years of evidence now show it lowering glucose, reducing cardiovascular events by a fifth in people who did not even have diabetes, slowing kidney disease progression by a quarter, and sustaining weight loss across four years of follow-up — with a serious adverse event rate that came in below placebo.
The deeper shift is conceptual. For a long time, weight was framed as a matter of resolve, and the medicines available were too weak to challenge that framing. GLP-1 receptor agonists demonstrated that appetite is a signalling system, that the system can be modulated, and that doing so improves hard clinical outcomes rather than just numbers on a scale. That is a genuinely different foundation for thinking about metabolic health.
For a closer look at how the individual compounds in this class compare, our Info Center covers each one, and the metabolic category groups them by research application.
Ozempic®, Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk A/S. Peptides Costa Rica is not affiliated with, endorsed by, or sponsored by Novo Nordisk, and does not sell these branded products. This article is provided for educational and informational purposes only. It is not medical advice, and it is not intended to diagnose, treat, cure or prevent any condition. Semaglutide is a prescription medicine and should only be used under the supervision of a licensed healthcare professional. Products offered by Peptides Costa Rica are intended strictly for laboratory research use only. They are not approved or licensed by the FDA for the prevention, diagnosis, treatment or cure of any disease. Not for human or veterinary use.
